Mullerian adenosarcomas: An immunophenotypic analysis of 35 cases

American Journal of Surgical Pathology

Volumn 32, Issue 7, 2008, Pages 1013-1021

  Soslow, Robert A ^a   Ali, Asya ^a   Oliva, Esther ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AR; C Kit; Calretinin; CD10; Cytokeratin; D34; Desmin; ER; Inhibin; Ki 67; Mullerian mesodermal adenosarcoma; Muscle actin; PR; Sarcomatous overgrowth; WT1

Indexed keywords

ANDROGEN RECEPTOR; CALRETININ; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN AE1; CYTOKERATIN AE3; DESMIN; ESTROGEN RECEPTOR; INHIBIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR; WT1 PROTEIN; TUMOR MARKER;

ADENOSARCOMA; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLON TUMOR; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MUELLERIAN DUCT; MYOBLAST; PROTEIN EXPRESSION; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EMBRYONAL RHABDOMYOSARCOMA; ENDOMETRIUM SARCOMA; FIBROMA; METABOLISM; METHODOLOGY; MIXED MULLERIAN TUMOR; PATHOLOGY; STROMA CELL; UTERUS CANCER;

ADENOFIBROMA; ADENOSARCOMA; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIXED TUMOR, MULLERIAN; RHABDOMYOSARCOMA, EMBRYONAL; SARCOMA, ENDOMETRIAL STROMAL; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 47249160307     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318161d1be     Document Type: Article

References (54)

1. Agoff SN, Grieco VS, Garcia R, et al. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol. 2001;9:164-169. 1020
2. Amant F, Schurmans K, Steenkiste E, et al. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol. 2004;93:680-685.
3. Amant F, Steenkiste E, Schurmans K, et al. Immunohistochemical expression of CD10 antigen in uterine adenosarcoma. Int J Gynecol Cancerl. 2004;14:1118-1121.
4. Ansink AC, Cross PA, Scorer P, et al. The hormonal receptor status of uterine carcinosarcomas (mixed mullerian tumours): an immu-nohistochemical study. J Clin Pathol. 1997;50:328-331.
5. Aubry MC, Myers JL, Colby TV, et al. Endometrial stromal sarcoma metastatic to the lung: a detailed analysis of 16 patients. Am J Surg Pathol. 2002;26:440-449.
6. Bhargava R, Shia J, Hummer AJ, et al. Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains. Mod Pathol. 2005;18: 40-47.
7. Binder SW, Nieberg RK, Cheng L, et al. Histologic and immunohistochemical analysis of nine endometrial stromal tumors: an unexpected high frequency of keratin protein positivity. Int J Gynecol Pathol. 1991;10:191-197.
8. Bocklage T, Lee KR, Belinson JL. Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol. 1992;44:104-109.
9. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90:170-176.
10. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113:374-382.
11. Clement PB. Mullerian adenosarcomas of the uterus with sarcoma-tous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol. 1989;13:28-38.
12. Clement PB, Scully RE. Extrauterine mesodermal (mullerian) adenosarcoma: a clinicopathologic analysis of five cases. Am J Clin Pathol. 1978;69:276-283.
13. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21:363-381.
14. Clement PB, Scully RE. Endometrial stromal sarcomas of the uterus with extensive endometrioid glandular differentiation: a report of three cases that caused problems in differential diagnosis. Int J Gynecol Pathol. 1992;11:163-173.
15. Clement PB, Oliva E, Young RH. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol. 1996;15:222-229.
16. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopatho-logic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578.
17. Daya DA, Scully RE. Sarcoma botryoides of the uterine cervix in young women: a clinicopathological study of 13 cases. Gynecol Oncol. 1988;29:290-304.
18. Eichhorn JH, Young RH, Clement PB, et al. Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26: 1243-1258.
19. Farhood AI, Abrams J. Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol. 1991;22:224-230.
20. Ferguson SE, Gerald W, Barakat RR, et al. Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol. 2007;31:382-389.
21. Feroze M, Aravindan KP, Thomas M. Mullerian adenosarcoma of the uterine cervix. Indian J Cancerl. 1997;34:68-72.
22. Fox H, Harilal KR, Youell A. Mullerian adenosarcoma of the uterine body: a report of nine cases. Histopathology. 1979;3: 167-180.
23. Franquemont DW, Frierson HF Jr, Mills SE. An immunohisto-chemical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol. 1991;15:861-870.
24. Goldblum JR, Clement PB, Hart WR. Adenomyosis with sparse glands. A potential mimic of low-grade endometrial stromal sarcoma. Am J Clin Pathol. 1995;103:218-223.
25. Hensley ML. Uterine sarcomas and carcinomas: advances for advanced disease and updates on adjuvant therapy. American Society of Clinical Oncology 2006 Educational Book: 42nd Annual Meeting, June 2-6, 2006. Atlanta, GA. Alexandria, VA: American Society of Clinical Oncology; 2006:301-304.
26. Hino A, Hirose T, Seki K, et al. Adenosarcoma of the uterine cervix presenting as a cervical polyp. Pathol Int. 1998;48:649-652.
27. Inoue Fukuda H, Tanizawa O. Adenosarcomas originating from sites other than uterine endometrium. Int J Gynaecol Obstet. 1995; 48:299-306.
28. Jazaeri AA, Nunes KJ, Dalton MS, et al. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001;20:6965-6969.
29. Jones MW, Lefkowitz M. Adenosarcoma of the uterine cervix: a clinicopathological study of 12 cases. Int J Gynecol Pathol. 1995;14:223-229.
30. Kaku T, Silverberg SG, Major FJ, et al. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992;11:75-88.
31. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol. 2003;22:181-184.
32. Leath CA III, Straughn JM Jr, Conner MG, et al. Immunohisto-chemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med. 2004;49:71-75.
33. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histo-pathology. 2001;39:273-278.
34. Mikami Y, Hata S, Kiyokawa T, et al. Expression of CD10 in malignant mullerian mixed tumors and adenosarcomas: an im-munohistochemical study. Mod Pathol. 2002;15:923-930.
35. Moinfar F, Regitnig P, Tabrizi AD, et al. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch. 2004;444:410-414.
36. Navarro D, Cabrera JJ, Leon L, et al. Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. J Steroid Biochem Mol Biol. 1992;41:589-596.
37. Nucci MR, O'Connell JT, Huettner PC, et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol. 2001;25:455-463.
38. Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol. 2000;7:257-281.
39. Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26:403-412.
40. Raspollini MR, Amunni G, Villanucci A, et al. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment. Clin Cancerl Res. 2004;10: 3500-3503.
41. Raspollini MR, Pinzani P, Simi L, et al. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT. Gynecol Oncol. 2005;98:334-335.
42. Raspollini MR, Susini T, Amunni G, et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol. 2005;96:159-167.
43. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunopheno-typic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
44. Rush DS, Tan J, Baergen RN, et al. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol. 2001;25: 253-258.
45. Seidman JD, Chauhan S. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol. 2003;22: 75-82.
46. Sumathi VP, Al-Hussaini M, Connolly LE, et al. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol. 2004;23:241-247.
47. Sutton GP, Stehman FB, Michael H, et al. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol. 1986;68: 709-714.
48. Van Mieghem T, Abeler VM, Moerman P, et al. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecol Oncol. 2005;99:493-496.
49. Verschraegen CF, Vasuratna A, Edwards C, et al. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep. 1998;5:939-944.
50. World Health Organization. Tumours of soft tissue and bone. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: International Agency for Research in Cancerl; 2002.
51. World Health Organization. Tumours of the breast and female genital organs. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: International Agency for Research in Cancer; 2003.
52. Yantiss RK, Clement PB, Young RH. Neoplastic and pre-neoplastic changes in gastrointestinal endometriosis: a study of 17 cases. Am J Surg Pathol. 2000;24:513-524.
53. Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol. 2002;26:1142-1150.
54. Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer. 1981;48: 354-366.